Clene Inc. Taps into Potential ALS Breakthrough with FDA In-Person Meeting on CNM-Au8 Development
In a significant development for neurodegenerative disease treatment, Clene Inc. (Nasdaq: CLNN), along with its wholly owned subsidiary Clene Nanomedicine Inc. has been granted an in-person meeting with senior leadership at the U.S. Food and Drug Administration (FDA) to discuss its groundbreaking treatment for amyotrophic lateral sclerosis (ALS), CNM-Au8. Scheduled to take place before the end of November 2024, this meeting underscores the company’s commitment to advancing its innovative approaches in the fight against ALS and potentially other neurodegenerative diseases.
The Context of Clene’s Initiative
Clene Inc. has positioned itself as a late clinical-stage biopharmaceutical company focusing on improving mitochondrial health and protecting neuronal function — crucial factors in combatting ALS and multiple sclerosis (MS). ALS, a progressive disease that devastates nerve cells in the brain and spinal cord, currently has no cure, leaving many patients desperately searching for effective treatment options. Thus, Clene’s work to develop CNM-Au8 offers a beacon of hope amid escalating challenges faced by patients and healthcare providers alike.
Comments